129
Participants
Start Date
May 31, 2024
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2027
combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
"Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX(Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2)/ TOMIRI(Raltitrexed 2 mg/m2 ,Irinotecan 120mg/m2) Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle"
Fudan University Shanghai Cancer Center, Shanghai
Fudan University
OTHER